Allogene Calls Its Pivotal Lymphoma Interim Positive. $388.9M of Cash, Guided Into 2029. Shares Outstanding Up 51% This Year.

Allogene Therapeutics makes CAR T cells from healthy donors, stored in advance, and is testing its lead product, cema-cel, in ALPHA3, a randomized Phase 2 trial the company calls pivotal, in patients with large B-cell lymphoma who still show traces of disease after first-line treatment. At an April interim analysis, 7 of 12 cema-cel patients were MRD-negative against 2 of 12 under observation; the event-free survival endpoint remains blinded, with analyses due in mid-2027 and mid-2028. A $200.4M offering in April lifted cash and investments to $423.6M at June 30; they stood at $388.9M at September 30, with runway guided into 2029, and the share count rose 51% this year.

Analysis

Allogene Therapeutics is a South San Francisco biotechnology company, incorporated in 2017 and listed on the Nasdaq Global Select Market, that develops allogeneic CAR T-cell therapies: engineered T cells made from healthy donors rather than from each patient. It has no approved product and no product revenue. Its lead candidate, cemacabtagene ansegedleucel, or cema-cel, is a CD19-targeted CAR T in ALPHA3, a randomized Phase 2 trial the company calls pivotal, in first-line large B-cell lymphoma. Behind it are ALLO-329, a dual CD19 and CD70 CAR T in a Phase 1 autoimmune trial, and ALLO-316, a CD70 CAR T in kidney cancer that the company is seeking to partner. The 10-K says the company has treated more than 200 patients across six clinical studies.

The third-quarter report on November 5 is why the desk is writing now. The net loss for the quarter ended September 30 was $50.4M, or $0.15 per share, against $41.4M, or $0.19, a year earlier, as research and development expense rose 35% to $41.9M. Cash, cash equivalents and investments were $388.9M, and the company kept its runway guidance at into 2029. The quarter closed a year of change: an interim analysis of ALPHA3 and a $200.4M underwritten offering in April, a new chief executive and RMAT and Fast Track designations for cema-cel in July. Updated ALLO-329 data are scheduled for ACR Convergence on November 9.

The Human Translation: Most CAR T treatments are built from each patient's own immune cells, a process that takes weeks. Allogene makes CAR T cells from healthy donors in advance, so they can be given soon after a blood test shows that hidden lymphoma remains after first treatment. Its main trial asks whether treating those patients early, before the cancer returns, keeps it away longer. Early blood-test results favored treatment. The answers that count, on relapse, are due in 2027 and 2028.

The platform starts with T cells from healthy donors. Allogene engineers them to lack a functional T-cell receptor, which reduces the risk of graft-versus-host disease, using TALEN gene editing licensed from Cellectis for oncology and CRISPR licensed from Arbor Biotechnologies for autoimmune programs. Oncology products also inactivate CD52. The newer Dagger technology adds a CAR against CD70, designed to eliminate the activated host T cells that would otherwise reject the donor cells, and so to reduce or remove the need for chemotherapy conditioning. The products are frozen and held in inventory, and the 10-K says a manufacturing run could make about 100 doses or more at scale.

Cema-cel, formerly ALLO-501A, replaced ALLO-501 in 2021 with an optimized construct and process. Its rights come from a license with Servier, under which Allogene holds U.S., EU and U.K. commercial rights. In the Phase 1 ALPHA and ALPHA2 studies, 33 CAR T-naive patients with relapsed or refractory large B-cell lymphoma were treated. At the regimen then selected for Phase 2, in 12 patients, the 10-K reports an overall response rate of 67% and a complete response rate of 58% as of September 26, 2024, with no dose-limiting toxicities, graft-versus-host disease, ICANS or high-grade cytokine release syndrome. That regimen included ALLO-647, an anti-CD52 antibody the company has since dropped.

ALPHA3 targets a different moment: patients who finish first-line treatment but still show minimal residual disease, or MRD, on Natera's investigational CLARITY blood test. About 220 such patients are to be randomized to cema-cel or to observation, the current standard, with event-free survival as the primary endpoint; the company says the trial is powered to detect a 50% reduction in the risk of an event. The design changed in August 2025. A patient in the arm that added ALLO-647 to standard fludarabine and cyclophosphamide had a Grade 5, or fatal, adverse event: hepatic failure on Day 54 after infusion, which the company said was believed to have resulted from disseminated adenovirus infection in the setting of immune suppression. The company attributed the event to the use of ALLO-647 and said it was deemed unrelated to cema-cel. That arm closed to enrollment, and after consulting the FDA and with the trial's Data and Safety Monitoring Board, the company selected standard conditioning; the trial continued against observation.

The interim futility analysis, announced April 13, 2026, and described in the third-quarter release as positive, covered the first 24 patients randomized in the two arms still open to enrollment, 12 per arm, at the Day 45 MRD assessment. The company reported MRD negativity in 7 of 12 cema-cel patients, or 58.3%, against 2 of 12 under observation, or 16.7%, and a median 97.7% decline in circulating tumor DNA on cema-cel against a 26.6% rise on observation. It described cema-cel as generally well tolerated, with no cytokine release syndrome, ICANS, graft-versus-host disease or treatment-related serious adverse events; other neurologic events, all low grade, such as headache, dizziness and numbness or tingling, occurred in 6 of 12 cema-cel patients against 1 of 12 under observation. It said 10 of 12 cema-cel patients were managed entirely as outpatients after infusion and the other two were briefly hospitalized for events deemed unrelated to cema-cel. The event-free survival endpoint remains blinded. MRD clearance is a biomarker; the trial's primary endpoint is event-free survival.

The trial is now an enrollment exercise. The FDA granted cema-cel RMAT and Fast Track designations in July 2026 for first-line consolidation in high-risk large B-cell lymphoma. The company passed 80 activated sites about six months ahead of its 2026 goal and expects about 100 by year-end, mostly in the U.S., with sites in Canada, Australia and South Korea; community centers accounted for about a third of screening and infusions. It expects enrollment to finish by the end of 2027, an interim event-free survival analysis in mid-2027 and the primary analysis in mid-2028, and says positive results could support a biologics license application. It has hired a vice president for market access and plans an investor event at ASH in December.

ALLO-329 is the autoimmune program. It targets CD19 on B cells and uses Dagger's CD70 arm to resist rejection, with the aim of reducing or eliminating chemotherapy conditioning. The FDA cleared its IND in January 2025 and granted three Fast Track designations in April 2025. The Phase 1 RESOLUTION trial, a 3+3 dose escalation starting at 20 million cells, enrolls patients with lupus, myositis and systemic sclerosis under three conditioning approaches: none, cyclophosphamide alone, and fludarabine with cyclophosphamide. As of the May 13 release, nine patients had been treated, six with cyclophosphamide at 20 million or 40 million cells and three at 20 million cells with no conditioning, and the company described early signs of clinical activity and favorable tolerability without giving figures. Updated data, with a focus on systemic sclerosis, are scheduled for a poster on November 9.

ALLO-316 targets CD70 in advanced renal cell carcinoma and holds RMAT designation. In the Phase 1b expansion cohort reported at ASCO in June 2025, 20 patients received 80 million cells after standard conditioning; the confirmed response rate was 25%, or 5 of 20, and 31%, or 5 of 16, in patients with high CD70 expression, with four of the five responses ongoing. In the cohort's 22-patient safety population, which includes two patients who received conditioning but not ALLO-316, the company reported cytokine release syndrome in 68%, none at grade 3 or higher, and IEC-HS, an inflammatory syndrome, in 36%, including one grade 3 and one grade 4 case; earlier dose-finding cohorts had fatal treatment-related adverse events. Enrollment in the Phase 1b cohort is complete and further standard dosing is paused pending durability results; clinical findings were discussed at SITC on November 5, and the company is exploring partnerships. Programs in myeloma, leukemia, small cell lung cancer and gastric cancer are deprioritized.

The agreements shape the economics. A 2018 asset contribution agreement with Pfizer brought licenses to ALLO-715, ALLO-605 and ALLO-316, and Cellectis licenses Allogene TALEN for 15 cancer targets. Under the Servier license, Allogene would pay Servier up to EUR 75.0M of milestones for initial indications, EUR 55.0M for each subsequent indication and up to EUR 80.0M of sales milestones, plus royalties of 10% outside the U.S. and from the low tens to the mid teens in the U.S. The 10-Q says no milestones were achieved and no royalties paid under the Pfizer, Cellectis or Servier agreements in the first nine months of 2025 or 2026. A EUR 20.0M escrow held for a possible cema-cel milestone was returned in February 2026, bringing in $23.7M. Allogene has committed about $37.3M to Natera for the MRD assay.

The third quarter shows spending rising with enrollment. Research and development expense was $41.9M, up from $31.2M a year earlier and from $30.7M in the second quarter, and included $1.6M of Natera milestones. General and administrative expense was $12.9M, against $13.7M. Total operating expenses were $54.8M, up 22%. Interest and other income was $4.9M, against $3.9M. For nine months, research and development fell 14% to $104.7M, general and administrative rose 11% to $47.8M, and the net loss was $135.7M, or $0.44 per share, against $152.1M, or $0.70. The nine months included $4.6M of non-cash collaboration revenue from the May 12 termination of the license to Overland Therapeutics, the former joint venture, and $27.7M of stock-based compensation.

The annual record shows the reset. Research and development expense fell 22% to $150.2M in 2025 from $192.3M, general and administrative fell 13% to $56.8M, and the net loss narrowed to $190.9M, or $0.87 per share, from $257.6M, or $1.32. On May 12, 2025 the board approved a reduction of about 28% of the workforce, with charges of $4.7M including $1.3M of equipment impairment. The quarterly net loss fell from $59.7M in the first quarter of 2025 to $38.8M in the fourth, then rose to $42.6M, $42.7M and $50.4M through 2026. The accumulated deficit reached $2.15B at September 30, 2026.

Cash, cash equivalents and investments fell from $373.1M at the end of 2024 to $258.3M a year later, rose to $266.9M in March 2026 with at-the-market proceeds and the returned escrow, and then to $423.6M after the April offering, before ending September at $388.9M, down $34.7M in the quarter. Nine-month operating cash use was $81.0M, or about $104.5M excluding the $23.5M escrow return on the desk's arithmetic. The runway guide moved from the second half of 2027 in November 2025 to the first quarter of 2028 in March and, after the offering, into the first quarter of 2029 in May; the August and November releases say into 2029. Guidance calls for about $165M of 2026 operating cash expense. GAAP guidance of about $225M would leave about $72.6M for the fourth quarter, on the desk's arithmetic. The 10-Q says cash will fund operations for at least 12 months.

The share count is the cost of that runway. Common shares outstanding rose from 229,413,523 at the end of 2025 to 346,279,825 at September 30, up 51%, and were 346,467,307 on November 3. The April offering sold 100,200,000 shares, including a partial exercise of the underwriters' option, for $200.4M gross and about $187.9M net, and at-the-market sales added 12,476,533 shares for $20.7M net, all in the first quarter. In June the company filed a prospectus supplement for up to $135.0M of at-the-market sales through TD Securities; the 10-Q says no shares were sold under it through September 30, so that capacity remains on file. Stockholders also doubled authorized shares to 800M. There are 37.9M options, 16.7M unvested restricted stock units and 4.7M performance-based units outstanding.

Manufacturing is in-house for clinical supply. Allogene makes its products at Cell Forge 1, a cGMP facility in Newark, California, on a lease of about 118,000 square feet that runs to July 2036, and relies on third parties for raw materials including viral vectors. Headquarters in South San Francisco covers about 68,000 square feet plus an expansion, on leases to March 2032, with part of the space subleased. Operating lease liabilities were $76.9M at September 30, 2026. The 10-K lists reduced manufacturing operations among its facility risks, and dependence on contract research and manufacturing organizations among its operating risks.

Leadership changed this year. David Chang, a co-founder and chief executive for eight years, stepped down on June 30, 2026 and remains a director. Zachary Roberts, who joined in 2023 as executive vice president of research and development and chief medical officer after roles at Instil Bio and Kite Pharma, became president and chief executive on July 1 and joined the board. Arie Belldegrun, a co-founder, is executive chairman. Separately, general and administrative expense in the second quarter was $20.8M, including $10.3M of stock-based compensation, before falling to $12.9M in the third; the earnings releases give no reason for the rise. Geoffrey Parker, executive vice president and chief financial officer, gave notice on August 31 of his retirement, effective November 6, 2026; the 8-K does not name a successor.

The risks the filings name are concrete. Clinically, the interim result is a biomarker comparison in 24 patients, and the event-free survival endpoint is unknown. On safety, the ALPHA3 death led to the closure of an arm, and the 10-K warns that undesirable side effects could halt development or limit commercial potential and that the event could bring regulatory action or product liability claims. Regulatory risk includes the fact that no CAR T is approved for first-line consolidation in this disease and that the MRD test may need its own approval as a companion diagnostic. Allogene depends on Cellectis and Servier for TALEN and cema-cel rights. Financing needs remain substantial, with dilution the main tool so far. Competition spans autologous and allogeneic CAR T, bispecific antibodies and antibody-drug conjugates.

The scenario map has three branches. In the first, ALPHA3 enrolls on schedule, the mid-2027 interim event-free survival analysis supports continuing toward the mid-2028 primary analysis, ALLO-329 data justify a Phase 2 regimen, and spending stays near guidance, leaving the $135.0M at-the-market capacity unused into 2028. In the second, enrollment slips or the interim analysis is inconclusive, the timeline extends, and the company returns to the equity market before the primary readout. In the third, event-free survival does not separate from observation or a new safety signal emerges, and the company must reshape its pipeline around ALLO-329 or partnerships while funding a smaller plan.

The checkpoint set, stated fully. First, the ALLO-329 data presented at ACR Convergence on November 9 and released afterward, especially in systemic sclerosis and without conditioning. Second, ALPHA3 site activation against about 100 by year-end and enrollment against about 220 patients by the end of 2027. Third, the ASH investor event in December. Fourth, fourth-quarter operating expenses against the 2026 guidance and the year-end cash balance against $388.9M. Fifth, any sales under the $135.0M at-the-market supplement. Sixth, the mid-2027 interim event-free survival analysis. Seventh, the appointment of a chief financial officer, and any partnership for ALLO-316 or the deprioritized programs.

The Human Translation

Most CAR T treatments are built from each patient's own immune cells, which takes weeks. Allogene makes CAR T cells from healthy donors in advance, so they can be given soon after a blood test shows lymphoma remains after first treatment. Its main trial asks whether treating those patients early, before relapse, keeps the cancer away longer. Early blood-test results favored treatment; the relapse results come in 2027 and 2028. A large stock sale funded the wait.

Bottom Line

Watch ALPHA3 enrollment against about 220 patients by the end of 2027 and site activation against about 100 by year-end, then the mid-2027 interim event-free survival analysis. Watch the ALLO-329 data from November 9, fourth-quarter spending against 2026 guidance, the year-end cash balance against $388.9M, and whether any of the $135.0M at-the-market capacity is used before the readouts.

Quick Facts

More from the research desk: NAGE, MDAI, PDLB, GAU, and the full library